Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates
Authors
Keywords
-
Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 56, Issue 3, Pages 733-737
Publisher
Wiley
Online
2016-12-15
DOI
10.1002/anie.201608292
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficient Palladium-Assisted One-Pot Deprotection of (Acetamidomethyl)Cysteine Following Native Chemical Ligation and/or Desulfurization To Expedite Chemical Protein Synthesis
- (2016) Suman Kumar Maity et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates
- (2016) Sujiet Puthenveetil et al. BIOCONJUGATE CHEMISTRY
- Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
- (2016) F. Li et al. CANCER RESEARCH
- New developments for antibody-drug conjugate-based therapeutic approaches
- (2016) Bart ECG de Goeij et al. CURRENT OPINION IN IMMUNOLOGY
- Erratum: Corrigendum: Recent advances in the construction of antibody–drug conjugates
- (2016) Vijay Chudasama et al. Nature Chemistry
- Dual modification of biomolecules
- (2016) Antoine Maruani et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
- (2015) Nicholas McGranahan et al. CANCER CELL
- A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
- (2015) S.-F. Yu et al. CLINICAL CANCER RESEARCH
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
- (2015) R. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
- (2015) Antoine Maruani et al. Nature Communications
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
- (2014) Michelle A. Fanale et al. JOURNAL OF CLINICAL ONCOLOGY
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
- (2014) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- Labeling Thiols on Proteins, Living Cells and Tissues with Enhanced Emission Induced by FRET
- (2013) Yue Yuan et al. Scientific Reports
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
- (2010) Y. V. Kovtun et al. CANCER RESEARCH
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer
- (2008) C. O'Brien et al. CANCER RESEARCH
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now